Manufacturing Made Simple Podcast
Sep 16, 2026 · 30 min · 9 segments
Resilience strategies for volatile markets: safety stock models, nearshoring trends, pharma serialization requirements under DSCSA, demand forecasting frameworks, and the supplier relationship…
Andrew CheungHost
[upbeat music] So the first resilience strategy is called safety stock, which is maintaining a buffer inventory of critical inputs above your immediate production needs to absorb supply disruptions without production downtime.
Safety stock is not a new concept, but I want to push past the intuitive version of keep more on hand, uh, and move it into the framework for deciding how much to keep on hand for which materials, because those are the very different questions, and they also carry very different answers depending on the specific risk profile of each input.
The right safety stock level for any given material is the function of three variables: demand variability, supply lead time, and supply risk.
Demand variability is how predictably you can forecast how much material you'll need in a given period.
A commodity ingredient used across multiple product lines in relatively stable volumes has low demand variability.
A hero ingredient used exclusively in one product whose sales are highly seasonal has a high demand variability.
Supply lead time is how long it takes to receive a new shipment after you place an order, from ordering to delivery at your dock, which includes transit time and any quality release holds and testing that's needed.
Supply risk is the probability and potential duration of a supply disruption from your primary source.
A material with low demand variability, short lead time, and low supply risk needs minimal safety stock, maybe two or four weeks of coverage at the most, I would say.
Um, but a material with a high demand variability, a long lead time from overseas sourcing, and moderate supply risk from a single qualified supplier might need a twelve to twenty-four week, um, safety stock to provide adequate protection against a disruption.
The mistake that I see most commonly is companies applying a flat safety stock rule, two weeks of coverage for everything, or whatever the finance team agreed to as a working capital target, rather than differentiating by material risk profile.
That approach leaves you overstocked on low risk commodities and catastrophically understocked on the materials that are actually likely to disrupt your production For pharmaceutical manufacturers, safety stock decisions, uh, for APIs need to account for an additional constraint, the potential impact of a supply disruption on patients.
A drug shortage is a public health event, and the FDA has made it clear through its drug shortage reporting requirements and its guidance on supply chain robustness that pharmaceutical companies have a responsibility to maintain, uh, s- the supply continuity for critical medicines.
That responsibility should be factored explicitly into safety stock decisions for APIs and products where the drug shortage consequence is significant.
It consumes working capital, it requires warehouse space, and carries the risk of expiry or obsolescence if demand forecasts are wrong.
The right safety model balances supply chain resilience against the cost of carrying that resilience.
The goal is not maximum safety stock, it's optimal safety stock for each material-specific risk profile.
That optimization is worth the time to do properly, and it should be revisited at least annually as supply chain conditions change.
[upbeat music] So the first resilience strategy is called safety stock, which is maintaining a buffer inventory of critical inputs above your immediate production needs to absorb supply disruptions without production downtime.
Safety stock is not a new concept, but I want to push past the intuitive version of keep more on hand, uh, and move it into the framework for deciding how much to keep on hand for which materials, because those are the very different questions, and they also carry very different answers depending on the specific risk profile of each input.
The right safety stock level for any given material is the function of three variables: demand variability, supply lead time, and supply risk.
Demand variability is how predictably you can forecast how much material you'll need in a given period.
A commodity ingredient used across multiple product lines in relatively stable volumes has low demand variability.
A hero ingredient used exclusively in one product whose sales are highly seasonal has a high demand variability.
Supply lead time is how long it takes to receive a new shipment after you place an order, from ordering to delivery at your dock, which includes transit time and any quality release holds and testing that's needed.
Supply risk is the probability and potential duration of a supply disruption from your primary source.
A material with low demand variability, short lead time, and low supply risk needs minimal safety stock, maybe two or four weeks of coverage at the most, I would say.
Um, but a material with a high demand variability, a long lead time from overseas sourcing, and moderate supply risk from a single qualified supplier might need a twelve to twenty-four week, um, safety stock to provide adequate protection against a disruption.
The mistake that I see most commonly is companies applying a flat safety stock rule, two weeks of coverage for everything, or whatever the finance team agreed to as a working capital target, rather than differentiating by material risk profile.
That approach leaves you overstocked on low risk commodities and catastrophically understocked on the materials that are actually likely to disrupt your production For pharmaceutical manufacturers, safety stock decisions, uh, for APIs need to account for an additional constraint, the potential impact of a supply disruption on patients.
A drug shortage is a public health event, and the FDA has made it clear through its drug shortage reporting requirements and its guidance on supply chain robustness that pharmaceutical companies have a responsibility to maintain, uh, s- the supply continuity for critical medicines.
That responsibility should be factored explicitly into safety stock decisions for APIs and products where the drug shortage consequence is significant.
It consumes working capital, it requires warehouse space, and carries the risk of expiry or obsolescence if demand forecasts are wrong.
The right safety model balances supply chain resilience against the cost of carrying that resilience.
The goal is not maximum safety stock, it's optimal safety stock for each material-specific risk profile.
That optimization is worth the time to do properly, and it should be revisited at least annually as supply chain conditions change.
The rest of this transcript — segmented and speaker-labeled, so you land on the exact moment something was said
Search every transcript — by keyword, by phrase, or by meaning, across every show Radar indexes
Trends — what is surging across podcasts, measured against its own baseline
Alerts — when a name you follow appears in a newly indexed episode
No account is needed to search Radar.
